Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Heart failure patients may benefit from simple nutrient supplements

NCT ID NCT07234422

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether taking selenium and coenzyme Q10 (CoQ10) supplements can reduce heart failure-related hospital visits and deaths. About 1,100 adults with chronic heart failure will receive either the supplements or a placebo alongside their usual care. The goal is to see if these natural nutrients offer a safe way to improve heart health outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 1,100 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2026

Expected to finish

Dec 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age \>18 years * Outpatients with chronic HF, NYHA II - ambulatory IV * Serum NT-proBNP concentrations \>600 pg/mL (71 pmol/L) if in sinus rhythm; \>1000pg/mL (118 pmol/L) if in Atrial fibrillation\* Exclusion Criteria: * History of myocardial infarction, myocarditis, percutaneous intervention, cardiac surgery or stroke \<30 days * The presence of a mechanical assist device * Scheduled for mechanical assist device or heart transplant * Other non-cardiac conditions with limited life expectancy (\<1 year) * Amyloid, hypertrophic obstructive or constrictive cardiomyopathy * End stage kidney disease for which chronic intermittent peritoneal or haemodialysis * Unable to sign informed consent * (Unwilling to stop) use of over the counter supplements coQ10/selenium * Peanut and/or soy allergy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic heart failure are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    7 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • AUMC

    NOT_YET_RECRUITING

    Amsterdam, Netherlands

  • Amphia Ziekenhuis

    RECRUITING

    Breda, Netherlands

  • Catharina ziekenhuis Eindhoven

    NOT_YET_RECRUITING

    Eindhoven, Netherlands

  • Noordwest Ziekenhuisgroep

    NOT_YET_RECRUITING

    Alkmaar, Netherlands

  • St Antonius ziekenhuis

    NOT_YET_RECRUITING

    Nieuwegein, Netherlands

  • TREANT

    NOT_YET_RECRUITING

    Emmen, Netherlands

  • University Medical Center Groningen

    RECRUITING

    Groningen, 9713GZ, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.